Note: Hepatitis D (HDV) is one of the most severe forms of hepatitis. In order for it to replicate it requires the hepatitis B virus–both hepatitis viruses are serious and potentially life-threatening diseases. Currently, there are no approved medications to treat hepatitis D. Pegylated interferon has been used with some success–less than one-quarter of people who are treated have successfully resolved or cleared the hepatitis D virus. Some studies have combined hepatitis B antiviral medications with pegylated interferon, but again the success rates have been very low. This is why new medications are needed. While the press release below highlights a drug in early development it does offer much-needed hope for a new medication to treat this disease. If you have not been infected with hepatitis B, get vaccinated. It will protect against hepatitis D! Alan for www.hcvadvocate
MOSCOW, May 25, 2017 /PRNewswire/ —
MYR GmbH and its development partner Hepatera LLC today announced that the European Medicines Agency (EMA) granted “PRIME eligibility” for Myrcudex B, a first in class entry inhibitor for Hepatitis Delta (D) virus.
“It is very encouraging that the European regulator recognizes the importance of the unmet medical problem in hepatitis delta and is willing to support the development of Myrcludex B,” said Heiner Wedemeyer, MD, Professor at Hannover Medical School and Chairman of MYR’s Clinical Advisory Board. “The affected patients are in urgent need of new medications and we are looking forward to the upcoming results of the Phase 2b program with this innovative drug.”
“The combined efforts of academic research, public funding and small biotech development and venture activities allowed the clinical development of a completely new drug with a novel mode of action on both Hepatitis B and D virus. The enhanced dialog with EMA will now strongly facilitate further joint effort to bring Myrcludex B to the HDV/HBV co-infected patients in need as fast as possible,” commented Stephan Urban, PhD, DZIF-Professor for Translational Virology at the University of Heidelberg, inventor of the technology and collaboration partner of MYR GmbH and Hepatera LLC.